Lymphoma: all 5,624 studies

Page 19 of 57. Open to participants first (824), then studies with results posted, then the rest; newest registration first within each.

• Study of MLN8237 in Participants With Advanced Hematological MalignanciesCompletedNCT00697346Phase 1Results posted
• Lenalidomide in Combination With Rituximab in Treating Participants With Stage III/IV Indolent Non-Hodgkin LymphomaCompletedNCT00695786Phase 2Results posted
• Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin LymphomaCompletedNCT00695409Phase 2Results posted
• Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin LymphomaTerminatedNCT00691652Phase 1/2Results posted
• Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell TransplantCompletedNCT00691015Phase 2Results posted
• Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell LymphomaCompletedNCT00690560Phase 2Results posted
• Gleevec in Relapsed/Refractory T Cell Non-Hodgkin's LymphomaCompletedNCT00684411Phase 2Results posted
• T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic MalignanciesCompletedNCT00683046Phase 2Results posted
• Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell LymphomaCompletedNCT00670358Phase 1/2Results posted
• Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/LymphomaCompletedNCT00669877Phase 2Results posted
• Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT00669318Phase 2Results posted
• Trial of Vorinostat in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)CompletedNCT00667615Phase 1/2Results posted
• RFT5-dgA Immunotoxin in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Non-Hodgkin LymphomaTerminatedNCT00667017Phase 2Results posted
• Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer PainCompletedNCT00666211Phase 3Results posted
• Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With CancerCompletedNCT00661999Phase 3Results posted
• CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's LymphomaCompletedNCT00659425Phase 1Results posted
• Ph2 Gem/Nov/Rituxan Rel/Ref MantleCellCompletedNCT00656084Phase 2Results posted
• A Phase II Study of Single-Agent Lenalidomide in Subjects With Relapsed Or Refractory T-Cell Non-Hodgkin's LymphomaTerminatedNCT00655668Phase 2Results posted
• Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin LymphomaCompletedNCT00654732Phase 2Results posted
• Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma PatientsCompletedNCT00651755Not applicableResults posted
• Pilot Study of dMRI as a Tool for Early Evaluation of Tumor Response in Diffuse Large B-cell LymphomaTerminatedNCT00645359Results posted
• Oral Clofarabine for Relapsed/Refractory Non-Hodgkin LymphomaCompletedNCT00644189Phase 1/2Results posted
• A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular LymphomaCompletedNCT00636792Phase 2Results posted
• EL625 in Persistent Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaTerminatedNCT00636155Phase 2Results posted
• A Phase I/II Trial of VR-CHOP in Lymphoma PatientsCompletedNCT00634179Phase 1/2Results posted
• Rituximab, Lenalidomide, and Bortezomib in Mantle Cell LymphomaCompletedNCT00633594Phase 1/2Results posted
• Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)TerminatedNCT00632827Phase 2Results posted
• Clofarabine and Non-Myeloablative Allogeneic Hematopoietic TransplantationTerminatedNCT00626626Phase 1/2Results posted
• Pilot Trial of Intravenous Vitamin C in Refractory Non-Hodgkin Lymphoma (NHL)TerminatedNCT00626444Phase 2Results posted
• Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic LeukemiaTerminatedNCT00625729Phase 1/2Results posted
• Ofatumumab in Patients With Relapsed/Progressive Diffused Large B-Cell Lymphoma (DLBCL) Ineligible for or Relapse/Progression After TransplantCompletedNCT00622388Phase 2Results posted
• Donor Peripheral Stem Cell Transplant, Fludarabine, and Busulfan in Treating Patients With Hematologic CancersCompletedNCT00619645Phase 2Results posted
• Donor Stem Cell Transplant in Treating Patients With Previously Treated Lymphoma, Multiple Myeloma, or Chronic Lymphocytic LeukemiaCompletedNCT00612716Phase 2Results posted
• Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic CancerCompletedNCT00611351Phase 2Results posted
• Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate MofetilTerminatedNCT00608517Not applicableResults posted
• Rituximab, Pentostatin, Cyclophosphamide, and Lenalidomide in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT00602836Phase 2Results posted
• Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell LymphomaCompletedNCT00601718Phase 1/2Results posted
• Multi-day Doses in Prevention of Nausea and EmesisCompletedNCT00600353Phase 2Results posted
• Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System LymphomaCompletedNCT00594815Not applicableResults posted
• In-Vivo Activated T-Cell Depletion to Prevent GVHDTerminatedNCT00594308Not applicableResults posted
• Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell TransplantationCompletedNCT00591630Phase 2Results posted
• Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological CancerCompletedNCT00589563Phase 2Results posted
• Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHLCompletedNCT00588094Phase 2Results posted
• A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Participants With Chronic LeukemiaTerminatedNCT00587457Phase 1Results posted
• Phase II Trial of a Chemotherapy Alone Regimen of IV Busulfan (Busulfex), Melphalan and Fludarabine as Myeloablative Regimen Followed by an Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplant From an HLA-Identical, or HLA-Non Identical Related or Unrelated DonorCompletedNCT00582933Phase 2Results posted
• Ibritumomab Tiuxetan (Zevalin)+ Rituximab MaintenanceTerminatedNCT00582166Phase 2Results posted
• Phase 2 Hyper-CVAD/Rituximab for Untreated Mantle Cell LymphomaCompletedNCT00581854Phase 2Results posted
• Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell LymphomaCompletedNCT00581776Phase 2Results posted
• T-Reg Cell Kinetics, Stem Cell Transplant, REGALETerminatedNCT00578539Not applicableResults posted
• T-Regulatory Cell Kinetics, Stem Cell Transplantation, REGKINETerminatedNCT00578461Not applicableResults posted
• Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma PatientsCompletedNCT00577993Phase 3Results posted
• Cardiac Magnetic Resonance Imaging in Patients With Non-Hodgkin Lymphoma or Hodgkin Lymphoma Receiving DoxorubicinCompletedNCT00577798Results posted
• Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins LymphomaCompletedNCT00577629Phase 2Results posted
• A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and MelphalanCompletedNCT00577278Phase 2Results posted
• GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's LymphomaCompletedNCT00576758Phase 2Results posted
• Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin LymphomaCompletedNCT00574496Phase 2Results posted
• Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell TransplantCompletedNCT00571662Phase 2Results posted
• VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma, or Mantle Cell LymphomaCompletedNCT00571493Phase 1/2Results posted
• Immune Reconstitution After Autologous Hematopoietic Stem Cell Transpl for High-Risk LymphomaCompletedNCT00569309Not applicableResults posted
• Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological MalignanciesCompletedNCT00566696Phase 2Results posted
• Two Different Methods of Collecting Stem Cells For an Autologous Stem Cell Transplant in Treating Patients With Diffuse Large Cell LymphomaCompletedNCT00566228Phase 3Results posted
• Yttrium Y 90 Ibritumomab Tiuxetan, Etoposide, Cyclophosphamide, and an AHSCT in Non-Hodgkin's Lymphoma PatientsCompletedNCT00562978Phase 1/2Results posted
• Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)TerminatedNCT00562965Phase 3Results posted
• Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk LymphomaCompletedNCT00561418Phase 1Results posted
• Combination Chemotherapy With or Without Total-Body Irradiation Followed By Stem Cell Transplant in Treating Patients With Non-Hodgkin LymphomaCompletedNCT00559104Phase 2Results posted
• Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan RegimenCompletedNCT00556452Phase 1/2Results posted
• Bortezomib and Lenalidomide in Treating Patients With Relapsed or Refractory Mantle Cell LymphomaCompletedNCT00553644Phase 2Results posted
• Epratuzumab and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin LymphomaCompletedNCT00553501Phase 2Results posted
• Dasatinib in Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00550615Phase 1/2Results posted
• Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's LymphomaCompletedNCT00547534Phase 2Results posted
• AlloHCT From Matched Unrelated Donors in Pts w/ Advanced Hematologic Malignancies & DisordersCompletedNCT00547196Not applicableResults posted
• Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell CancerCompletedNCT00546377Phase 1/2Results posted
• Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other DisordersActive, not recruitingNCT00544115Phase 2Results posted
• A Study for Patients With Non-Hodgkin's LymphomasCompletedNCT00542919Phase 2Results posted
• Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic LeukemiaCompletedNCT00541034Phase 2Results posted
• Lenalidomide in Relapsed or Refractory Classical Hodgkin LymphomaCompletedNCT00540007Phase 2Results posted
• Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHDCompletedNCT00539695Phase 2Results posted
• Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid MalignanciesCompletedNCT00536978Phase 2Results posted
• High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid TumorsCompletedNCT00536601Not applicableResults posted
• Donor Lymphocyte Infusion in Treating Patients With Recurrent or Persistent Hematologic Cancer After Donor Stem Cell TransplantCompletedNCT00534118Not applicableResults posted
• CT-011 MAb in DLBCL Patients Following ASCTCompletedNCT00532259Phase 2Results posted
• Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or LymphomaCompletedNCT00531284Phase 1/2Results posted
• Non-Myeloablative Allogeneic Stem Cell TransplantationCompletedNCT00525876Not applicableResults posted
• DepoCyt for Active Lymphomatous or Leukemic MeningitisTerminatedNCT00523939Phase 2Results posted
• GM-CSF and Rituximab After Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin LymphomaCompletedNCT00521014Phase 2Results posted
• Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune SystemCompletedNCT00520130Phase 1/2Results posted
• A Study of MabThera (Rituximab) in Primary Central Nervous System Lymphoma.TerminatedNCT00517699Phase 2Results posted
• Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's LymphomaCompletedNCT00516217Phase 2Results posted
• Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell TransplantCompletedNCT00513474Phase 1Results posted
• Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular LymphomaTerminatedNCT00510887Phase 2Results posted
• Allogeneic Transplantation in Patients With Cutaneous T-Cell LymphomaCompletedNCT00506129Phase 2Results posted
• Autologous and Allogenic Transplantation With Campath-1H for T-Cell LymphomaTerminatedNCT00505921Phase 2Results posted
• Phase II Study of "VIPER" Chemotherapy in Rel/Ref DLBCLCompletedNCT00504751Phase 2Results posted
• Effect of Tight Control of Blood Glucose During Hyper-CVAD Chemotherapy For Acute Lymphocytic Leukemia (ALL)TerminatedNCT00500240Phase 3Results posted
• G-CSF Versus G-CSF Plus GM-CSF for Stem Cell Mobilization in NHL PatientsCompletedNCT00499343Phase 2Results posted
• Evaluation of the Safety and Efficacy of Nipent, Cytoxan, and RituxanCompletedNCT00496873Phase 2Results posted
• Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide,Doxorubicin, Vincristine, Predisolone) in Follicular Lymphoma (FL) PatientsCompletedNCT00494780Phase 2Results posted
• Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent LymphomasCompletedNCT00493467Phase 2Results posted
• Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent LymphomasTerminatedNCT00493454Phase 2Results posted
• Zevalin-beam for Aggressive LymphomaCompletedNCT00491491Phase 3Results posted

← Lymphoma overview